Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK.


CONCLUSIONS: The incidence of patients undergoing anti-VEGF therapy for nAMD increased substantially following NICE approval of ranibizumab (August 2008), and has been stable since 2009. This equates to an annual UK incidence of 26 850 (21 320 to 32 440) eyes, similar to NICE estimates. Patients eligible for blindness certification before treatment decreased by half from 2008-2012. Prospective data collection using an EMR system is invaluable for efficient monitoring of real-world clinical care.
PMID: 23813420 [PubMed – as supplied by publisher] (Source: The British Journal of Ophthalmology)